Facebook Facebook Share

Target Ovarian Cancer can provide statistics and spokespeople for journalists, and help you create headlines about ovarian cancer. For case studies, facts and statistics, spokespeople, or if you just want to clarify a piece of information, please call our PR team on 020 7923 5476 or email us.

Reporting on ovarian cancer: a journalist's guide

We have produced a guide for journalists reporting on ovarian cancer. At Target Ovarian Cancer, we're asking you to use this guide to help you report on ovarian cancer accurately and clearly, and to keep it handy, for future stories. 

Spokespeople who know their stuff

Whether it is a Target Ovarian Cancer spokesperson, a woman with ovarian cancer, or a leading health professional – you will find a depth of knowledge and opinion.

Case studies

Target Ovarian Cancer works with thousands of women with ovarian cancer. We can provide you with great case studies to bring your statistics to life or to create a specific feature about an impactful story.

Up-to-date statistics

We can help you report on new research and statistics, by putting them in perspective, and in plain English.

How we can help

Myth busting

We can help banish the myths surrounding ovarian cancer ‘risk factor’ links. Often the increase in risk is very small, or the study hasn’t attracted critical peer review to assess its validity. If in doubt, why not talk it through with us?

Great content

We can offer videos, B-roll, photography, graphics, links to our information standard-certified ovarian cancer advice and more for your use.

Raising awareness – dates to remember

Read our most recent news

Blog
football tournament
Monday 12 August 2019
This summer Giorgio combined his love of football with his drive to raise awareness by organising a charity tournament. Here he talks about how he planned the day and the amazing support he received from his family, friends and the local community... I lost my auntie to ovarian cancer eight years...
News
Thursday 25 July 2019
The National Institute for Health and Care Excellence (NICE) has for the first time approved a breakthrough ovarian cancer drug from the first round of treatment. Olaparib (Lynparza®) is one of a new generation of drugs known as PARP inhibitors, which work by stopping cancer cells from repairing...
Blog
Blog about ovarian cancer and obesity
Wednesday 24 July 2019
Risk factors connected to cancer are sometimes exaggerated in the media and public campaigns, and recently, the link between ovarian cancer and obesity has resurfaced. But is there actually a link between obesity and ovarian cancer, and how reliable is the science? In their recent campaign, Cancer...
Blog
It's time to TAKE OVAR GP training
Thursday 18 July 2019
An early diagnosis of ovarian cancer should be the norm. Too many women experience misdiagnosis and delays because GPs are not appropriately educated or supported to diagnose ovarian cancer quickly. Here’s what Target Ovarian Cancer are doing about it… Investing in education In the past 12 months...

Pages